These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 26800514)

  • 1. HER 2 immunohistochemistry for breast cancer cell blocks can be used in the same way as that used for histological specimens.
    Nishimura R; Okamoto N; Satou M; Kojima K; Tanaka S
    Diagn Cytopathol; 2016 Apr; 44(4):274-9. PubMed ID: 26800514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bright-field HER2 dual in situ hybridization (DISH) assay on breast cancer cell blocks: a comparative study with histological sections.
    Nishimura R; Okamoto N; Satou M; Kojima K; Tanaka S; Yamashita N
    Breast Cancer; 2016 Nov; 23(6):917-921. PubMed ID: 26746842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of HER2/neu status: a pilot study comparing HER2/neu dual in situ hybridization DNA probe cocktail assay performed on cell blocks to immunohistochemisty and fluorescence in situ hybridization performed on histologic specimens.
    Hartman AK; Gorman BK; Chakraborty S; Mody DR; Schwartz MR
    Arch Pathol Lab Med; 2014 Apr; 138(4):553-8. PubMed ID: 24678687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HER2 assessment by bright-field dual in situ hybridization in cell blocks of recurrent and metastatic breast carcinoma.
    Edelweiss M; Sebastiao APM; Oen H; Kracun M; Serrette R; Ross DS
    Cancer Cytopathol; 2019 Nov; 127(11):684-690. PubMed ID: 31544361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene protein detection platform--a comparison of a new human epidermal growth factor receptor 2 assay with conventional immunohistochemistry and fluorescence in situ hybridization platforms.
    Stålhammar G; Farrajota P; Olsson A; Silva C; Hartman J; Elmberger G
    Ann Diagn Pathol; 2015 Aug; 19(4):203-10. PubMed ID: 25921313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual-color dual-hapten in situ hybridization (D-DISH) - Comparison with fluorescence in situ hybridization (FISH) for HER2/neu testing in breast cancer.
    Gajaria PK; Tambe S; Pai T; Patil A; Desai SB; Shet TM
    Indian J Pathol Microbiol; 2020; 63(2):194-199. PubMed ID: 32317514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression in breast cancer FNA cell blocks and paired histologic specimens: A large retrospective study.
    Vohra P; Buelow B; Chen YY; Serrano M; Vohra MS; Berry A; Ljung BM
    Cancer Cytopathol; 2016 Nov; 124(11):828-835. PubMed ID: 27315045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The updated 2018 American Society of Clinical Oncology/College of American Pathologists guideline on human epidermal growth factor receptor 2 interpretation in breast cancer: comparison with previous guidelines and clinical significance of the proposed in situ hybridization groups.
    Woo JW; Lee K; Chung YR; Jang MH; Ahn S; Park SY
    Hum Pathol; 2020 Apr; 98():10-21. PubMed ID: 32027910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Droplet digital polymerase chain reaction detection of HER2 amplification in formalin fixed paraffin embedded breast and gastric carcinoma samples.
    Zhu Y; Lu D; Lira ME; Xu Q; Du Y; Xiong J; Mao M; Chung HC; Zheng G
    Exp Mol Pathol; 2016 Apr; 100(2):287-93. PubMed ID: 26626802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breast cancer HER2 equivocal cases: is there an alternative to FISH testing? A pilot study using two different antibodies sequentially.
    Yosepovich A; Avivi C; Bar J; Polak-Charcon S; Mardoukh C; Barshack I
    Isr Med Assoc J; 2010 Jun; 12(6):353-6. PubMed ID: 20928989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implications of the Updated 2013 American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations on Human Epidermal Growth Factor Receptor 2 Gene Testing Using Immunohistochemistry and Fluorescence In Situ Hybridization for Breast Cancer.
    Lim TH; Lim AS; Thike AA; Tien SL; Tan PH
    Arch Pathol Lab Med; 2016 Feb; 140(2):140-7. PubMed ID: 26910218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A gene-protein assay for human epidermal growth factor receptor 2 (HER2): brightfield tricolor visualization of HER2 protein, the HER2 gene, and chromosome 17 centromere (CEN17) in formalin-fixed, paraffin-embedded breast cancer tissue sections.
    Nitta H; Kelly BD; Padilla M; Wick N; Brunhoeber P; Bai I; Singh S; Ranger-Moore J; Bieniarz C; Tsuda H; Grogan TM
    Diagn Pathol; 2012 May; 7():60. PubMed ID: 22647525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER2 FISH classification of equivocal HER2 IHC breast cancers with use of the 2013 ASCO/CAP practice guideline.
    Fan YS; Casas CE; Peng J; Watkins M; Fan L; Chapman J; Ikpatt OF; Gomez C; Zhao W; Reis IM
    Breast Cancer Res Treat; 2016 Feb; 155(3):457-62. PubMed ID: 26895325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of HER2 gene status assessment by fluorescence in situ hybridization between histological sections and cytological specimens of breast cancer.
    Nishimura R; Kagawa A; Tamogami S; Kojima K; Satou M; Yamashita N; Teramoto N; Aogi K
    Breast Cancer; 2016 Mar; 23(2):211-5. PubMed ID: 25033760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reliability of immunocytochemistry and fluorescence in situ hybridization on fine-needle aspiration cytology samples of breast cancers: A comparative study.
    Acs B; Szekely N; Szasz AM; Lotz G; Szekely T; Istok R; Szekely E; Madaras L; Kulka J; Jaray B
    Diagn Cytopathol; 2016 Jun; 44(6):466-71. PubMed ID: 26990933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the types of candidate reference samples for quality control of human epidermal growth factor receptor 2 status detection.
    Li Y; Zhang R; Han Y; Lu T; Ding J; Zhang K; Lin G; Xie J; Li J
    Diagn Pathol; 2016 Sep; 11(1):85. PubMed ID: 27613595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Dako HercepTest and Ventana PATHWAY Anti-HER2 (4B5) Tests and Their Correlation With Fluorescent In Situ Hybridization in Breast Carcinoma.
    Lucas E; Jabbar SB; Molberg K; Fang Y; Xie XJ; Blacketer S; Sahoo S
    Appl Immunohistochem Mol Morphol; 2019 Jul; 27(6):403-409. PubMed ID: 31233398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New ASCO/CAP guideline recommendations for HER2 testing increase the proportion of reflex in situ hybridization tests and of HER2 positive breast cancers.
    Tchrakian N; Flanagan L; Harford J; Gannon JM; Quinn CM
    Virchows Arch; 2016 Feb; 468(2):207-11. PubMed ID: 26521061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bright-field HER2 dual in situ hybridization (DISH) assay vs fluorescence in situ hybridization (FISH): focused study of immunohistochemical 2+ cases.
    Gao FF; Dabbs DJ; Cooper KL; Bhargava R
    Am J Clin Pathol; 2014 Jan; 141(1):102-10. PubMed ID: 24343743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of breast cancer HER-2 receptor testing with immunohistochemistry and in situ hybridization.
    Shanmugalingam A; Hitos K; Pathmanathan N; Edirimmane S; Hughes TM; Ngui NK
    Breast Cancer Res Treat; 2023 Feb; 198(1):143-148. PubMed ID: 36604351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.